Coronaviruses Research in BRICS Countries

SARS-CoV-2 has infected more than 105 million people worldwide. During this pandemic, researchers and clinicians have been working to understand the molecular mechanisms that underpin viral pathogenesis by studying viral–host interactions. Now, with the global rollout of various COVID-19 vaccines—ba...

Full description

Saved in:
Bibliographic Details
HerausgeberIn:
Sonstige:
Year of Publication:2022
Language:English
Physical Description:1 electronic resource (168 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 03998nam-a2200877z--4500
001 993544623504498
005 20231214133133.0
006 m o d
007 cr|mn|---annan
008 202206s2022 xx |||||o ||| 0|eng d
035 |a (CKB)5720000000008321 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/84441 
035 |a (EXLCZ)995720000000008321 
041 0 |a eng 
100 1 |a Fielding, Burtram C.  |4 edt 
245 1 0 |a Coronaviruses Research in BRICS Countries 
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2022 
300 |a 1 electronic resource (168 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a SARS-CoV-2 has infected more than 105 million people worldwide. During this pandemic, researchers and clinicians have been working to understand the molecular mechanisms that underpin viral pathogenesis by studying viral–host interactions. Now, with the global rollout of various COVID-19 vaccines—based on the neutralization of the spike protein using different technologies—viral immunology and cell-based immunity are being investigated. Researchers are also studying how various SARS-CoV-2 genetic mutations will impact the efficacy of these COVID-19 vaccines. At the same time, various antiviral drugs have been identified or repurposed that have potential as anti-SARS-CoV-2 treatments. BRICS (Brazil, Russia, India, China, and South Africa) is the acronym used to associate five major emerging national economies. The BRICS countries are known for their significant influence on regional affairs, including being leaders in scientific and clinical research and innovation. This Special Issue includes researchers from BRICS countries, in particular South Africa, involved in the study of SARS-CoV-2 and COVID-19. Original articles, as well as new perspectives or reviews on the matter, were welcomed. Research in the fields of vaccine studies, pathogenesis, genetic mutations, viral immunology, and antiviral drugs were especially encouraged. 
546 |a English 
650 7 |a Medicine  |2 bicssc 
650 7 |a Epidemiology & medical statistics  |2 bicssc 
653 |a SARS-CoV-2 
653 |a E484K 
653 |a variant of Interest 
653 |a genomic epidemiology 
653 |a Brazil 
653 |a immunoassay 
653 |a SARS-CoV-2 nucleocapsid protein 
653 |a epitope coverage 
653 |a quantitative antibody binding 
653 |a protein microarray 
653 |a SARS-CoV-2 antibodies 
653 |a humoral response 
653 |a COVID-19 
653 |a nanotechnology 
653 |a detection 
653 |a treatment 
653 |a breakthrough 
653 |a VRDL 
653 |a Delta and Delta plus variant 
653 |a India 
653 |a vaccine 
653 |a dental aerosol-generating procedures 
653 |a extra-oral suction 
653 |a high-volume evacuation 
653 |a low-volume saliva ejector 
653 |a splatter 
653 |a aerosol 
653 |a convalescent plasma 
653 |a COVID-19 and nanotechnology 
653 |a nanomedicine in South Africa 
653 |a bioinformatics and vaccine development 
653 |a vaccine development in South Africa 
653 |a models 
653 |a different settings 
653 |a intervention strategies 
653 |a NSW 
653 |a coronavirus disease 2019 (COVID-19) 
653 |a severe acute respiratory syndrome coronavirus (SARS-CoV-2) 
653 |a neutralizing antibody (NAb) 
653 |a diabetes 
653 |a corticosteroids 
653 |a reverse zoonosis 
653 |a wildlife 
653 |a COVID-19 testing 
653 |a hospital mortality 
653 |a intubation 
776 |z 3-0365-4028-8 
776 |z 3-0365-4027-X 
700 1 |a Schäfer, Georgia  |4 edt 
700 1 |a Fielding, Burtram C.  |4 oth 
700 1 |a Schäfer, Georgia  |4 oth 
906 |a BOOK 
ADM |b 2023-12-15 05:43:46 Europe/Vienna  |f system  |c marc21  |a 2022-07-02 22:45:44 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337729600004498&Force_direct=true  |Z 5337729600004498  |b Available  |8 5337729600004498